{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Extract the useful subset of studies from trial complexity data\n",
    "\n",
    "Created by: Shemra Rizzo\n",
    "Date created: Nov 24, 2020"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Libraries\n",
    "import pandas as pd\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "#trial_complexity_data = pd.read_csv('trial_complexity.csv')\n",
    "\n",
    "trial_complexity_data = pd.read_csv('STUDYGO_24_06_2020.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(2304, 212)"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trial_complexity_data.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "studies_in_supplement = [\n",
    "'MO25515',\n",
    "'NO25390',\n",
    "'GO28053',\n",
    "'GO28625',\n",
    "'GO28754',\n",
    "'YO29232',\n",
    "'YO29233',\n",
    "'GO40241',\n",
    "'ML40471',\n",
    "'BO22334',\n",
    "'GO01298',\n",
    "'YP25623',\n",
    "'ML29167',\n",
    "'ML29538',\n",
    "'MO27782',\n",
    "'MO28113',\n",
    "'ML28589',\n",
    "'ML28879',\n",
    "'ML28794',\n",
    "'GO29058',\n",
    "'ML29282',\n",
    "'YO29296',\n",
    "'ML29662',\n",
    "'GO30182',\n",
    "'CO39083'\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "subset = trial_complexity_data[trial_complexity_data['STUDY_NUMBER'].isin(studies_in_supplement)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "columns_of_interest = ['STUDY_NUMBER', 'STUDY_FULL_TITLE', 'STUDY_SHORT_TITLE',\n",
    "       'STUDY_ACRONIM', 'STUDY_STATUS', 'DB_LOCK_FLAG', 'STUDY_PHASE_GROUP',\n",
    "       'STUDY_PHASE', 'STUDY_TYPE', 'THERAPEUTIC_AREA_REP', 'THERAPEUTIC_AREA',\n",
    "       'DTA', 'INDICATION', 'INDICATION_REP', 'DISTRIBUTION', 'COMPARISON',\n",
    "       'RANDOMIZATION', 'INTERVENTIONAL_STUDY_MODEL', 'BLINDING',\n",
    "       'EXECUTING_PARTY', 'OUTSOURCED', 'TARGET_NUM_COUNTRIES', 'OBJECTIVE',\n",
    "       'STUDY_KEYWORDS', 'INCLUSION_CRITERIA', 'NUM_OF_DRAGS', 'DRUG_PRIMARY_NAME',\n",
    "       'DRUG_NAMES', 'THERAPEUTIC_CLASSES', 'ACTUAL_ENROLLED_STUDY', 'PLANNED_ENROLLMENT',\n",
    "                       'WITHDRAWAL_RATIO' , 'SCREENING_RATE',\n",
    "       'ENROLLMENT_RATE', 'SCREEN_FAIL_RATIO', 'NUM_ALL_AE', 'NUM_AE',\n",
    "       'NUM_SAE', 'SCREENING_SUCCESS_RATIO',\n",
    "       'SCREEN_FAIL_DECLINED_TO_PARTICIPATE', 'SCREEN_FAIL_INCLUSION',\n",
    "       'SCREEN_FAIL_EXCLUSION', 'WITHDRAWN_ADVERSE_EVENTS',\n",
    "       'WITHDRAWN_SUBJECTIVE', 'WITHDRAWN_NON_COMPLIANCE',\n",
    "       'WITHDRAWN_PROTOCOL_DEVIATIONS', 'WITHDRAWN_SAFETY',\n",
    "       'WITHDRAWN_OTHER_PRE_SPECIFIED', 'WITHDRAWN_OTHER',\n",
    "       'WITHDRAWN_ADVERSE_EVENTS_RATIO', 'WITHDRAWN_SUBJECTIVE_RATIO',\n",
    "       'WITHDRAWN_NON_COMPLIANCE_RATIO', 'WITHDRAWN_PROTOCOL_DEVIATIONS_RATIO',\n",
    "       'WITHDRAWN_SAFETY_RATIO', 'WITHDRAWN_OTHER_PRE_SPECIFIED_RATIO',\n",
    "       'WITHDRAWN_OTHER_RATIO']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "subset = subset[columns_of_interest]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "# save subset\n",
    "subset.to_csv('trial_pathfinder_subset_in_supplement.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['STUDY_NUMBER', 'STUDY_FULL_TITLE', 'STUDY_SHORT_TITLE',\n",
       "       'STUDY_ACRONIM', 'STUDY_STATUS', 'DB_LOCK_FLAG', 'STUDY_PHASE_GROUP',\n",
       "       'STUDY_PHASE', 'STUDY_TYPE', 'THERAPEUTIC_AREA_REP', 'THERAPEUTIC_AREA',\n",
       "       'DTA', 'INDICATION', 'INDICATION_REP', 'DISTRIBUTION', 'COMPARISON',\n",
       "       'RANDOMIZATION', 'INTERVENTIONAL_STUDY_MODEL', 'BLINDING',\n",
       "       'EXECUTING_PARTY', 'OUTSOURCED', 'TARGET_NUM_COUNTRIES', 'OBJECTIVE',\n",
       "       'STUDY_KEYWORDS', 'INCLUSION_CRITERIA', 'EXCLUSION_CRITERIA',\n",
       "       'PAT_CRIT_MIN_AGE', 'PAT_CRIT_MAX_AGE', 'PAT_CRIT_GENDER',\n",
       "       'ACTUAL_TREATMENT_DURATION', 'NUM_OF_DRAGS', 'DRUG_PRIMARY_NAME',\n",
       "       'DRUG_NAMES', 'THERAPEUTIC_CLASSES', 'NUM_PRIMARY_ENDPOINTS',\n",
       "       'NUM_SECONDARY_ENDPOINTS', 'PRIMARY_ENDPOINTS', 'SECONDARY_ENDPOINTS',\n",
       "       'NUM_OF_ARMS', 'LIST_OF_ARMS', 'NUM_BIOMARKERS', 'LIST_BIOMARKERS',\n",
       "       'NUM_ACTUAL_STUDY_SITES', 'NUM_PLANNED_STUDY_SITES',\n",
       "       'ACTUAL_ENROLLED_STUDY', 'PLANNED_ENROLLMENT', 'WITHDRAWAL_RATIO',\n",
       "       'CYCLES', 'NR_PRIMARY_INVESTIGATORS', 'NUM_PROTOCOL_VERSION'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trial_complexity_data.columns[0:50]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['STUDY_NUMBER', 'STUDY_FULL_TITLE', 'STUDY_SHORT_TITLE',\n",
       "       'STUDY_ACRONIM', 'STUDY_STATUS', 'DB_LOCK_FLAG', 'STUDY_PHASE_GROUP',\n",
       "       'STUDY_PHASE', 'STUDY_TYPE', 'THERAPEUTIC_AREA_REP', 'THERAPEUTIC_AREA',\n",
       "       'DTA', 'INDICATION', 'INDICATION_REP', 'DISTRIBUTION', 'COMPARISON',\n",
       "       'RANDOMIZATION', 'INTERVENTIONAL_STUDY_MODEL', 'BLINDING',\n",
       "       'EXECUTING_PARTY', 'OUTSOURCED', 'TARGET_NUM_COUNTRIES', 'OBJECTIVE',\n",
       "       'STUDY_KEYWORDS', 'INCLUSION_CRITERIA', 'NUM_OF_DRAGS',\n",
       "       'DRUG_PRIMARY_NAME', 'DRUG_NAMES', 'THERAPEUTIC_CLASSES',\n",
       "       'WITHDRAWAL_RATIO', 'SCREENING_RATE', 'ENROLLMENT_RATE',\n",
       "       'SCREEN_FAIL_RATIO', 'NUM_ALL_AE', 'NUM_AE', 'NUM_SAE',\n",
       "       'SCREENING_SUCCESS_RATIO', 'SCREEN_FAIL_DECLINED_TO_PARTICIPATE',\n",
       "       'SCREEN_FAIL_INCLUSION', 'SCREEN_FAIL_EXCLUSION',\n",
       "       'WITHDRAWN_ADVERSE_EVENTS', 'WITHDRAWN_SUBJECTIVE',\n",
       "       'WITHDRAWN_NON_COMPLIANCE', 'WITHDRAWN_PROTOCOL_DEVIATIONS',\n",
       "       'WITHDRAWN_SAFETY', 'WITHDRAWN_OTHER_PRE_SPECIFIED', 'WITHDRAWN_OTHER',\n",
       "       'WITHDRAWN_ADVERSE_EVENTS_RATIO', 'WITHDRAWN_SUBJECTIVE_RATIO',\n",
       "       'WITHDRAWN_NON_COMPLIANCE_RATIO', 'WITHDRAWN_PROTOCOL_DEVIATIONS_RATIO',\n",
       "       'WITHDRAWN_SAFETY_RATIO', 'WITHDRAWN_OTHER_PRE_SPECIFIED_RATIO',\n",
       "       'WITHDRAWN_OTHER_RATIO'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "subset.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>STUDY_NUMBER</th>\n",
       "      <th>STUDY_FULL_TITLE</th>\n",
       "      <th>STUDY_SHORT_TITLE</th>\n",
       "      <th>STUDY_ACRONIM</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>DB_LOCK_FLAG</th>\n",
       "      <th>STUDY_PHASE_GROUP</th>\n",
       "      <th>STUDY_PHASE</th>\n",
       "      <th>STUDY_TYPE</th>\n",
       "      <th>THERAPEUTIC_AREA_REP</th>\n",
       "      <th>...</th>\n",
       "      <th>WITHDRAWN_SAFETY</th>\n",
       "      <th>WITHDRAWN_OTHER_PRE_SPECIFIED</th>\n",
       "      <th>WITHDRAWN_OTHER</th>\n",
       "      <th>WITHDRAWN_ADVERSE_EVENTS_RATIO</th>\n",
       "      <th>WITHDRAWN_SUBJECTIVE_RATIO</th>\n",
       "      <th>WITHDRAWN_NON_COMPLIANCE_RATIO</th>\n",
       "      <th>WITHDRAWN_PROTOCOL_DEVIATIONS_RATIO</th>\n",
       "      <th>WITHDRAWN_SAFETY_RATIO</th>\n",
       "      <th>WITHDRAWN_OTHER_PRE_SPECIFIED_RATIO</th>\n",
       "      <th>WITHDRAWN_OTHER_RATIO</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>GO40241</td>\n",
       "      <td>A PHASE III, DOUBLE-BLINDED, MULTICENTER, RAND...</td>\n",
       "      <td>Neoadjuvant NSCLC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Active</td>\n",
       "      <td>0</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>23.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.01</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>145</th>\n",
       "      <td>YO29233</td>\n",
       "      <td>A PHASE I, OPEN-LABEL STUDY TO ASSESS THE PHAR...</td>\n",
       "      <td>China PK  Study</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Active</td>\n",
       "      <td>0</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase Ib</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>85.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.71</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>192</th>\n",
       "      <td>MO28113</td>\n",
       "      <td>A TWO-PART, RANDOMIZED PHASE III, DOUBLE-BLIND...</td>\n",
       "      <td>Pertuzumab + chemo+: platinum resistant women</td>\n",
       "      <td>PENELOPE</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>37.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.18</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>209</th>\n",
       "      <td>ML29282</td>\n",
       "      <td>A PHASE IV, MULTICENTER, OPEN-LABEL, SINGLE-AR...</td>\n",
       "      <td>Open-label single arm study in first line advBC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 4</td>\n",
       "      <td>Phase IV</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>215</th>\n",
       "      <td>YP25623</td>\n",
       "      <td>A multi-center, open label, single arm, multip...</td>\n",
       "      <td>PK study of GA101 in Chinese patients</td>\n",
       "      <td>GERSHWIN</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase I</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>14.0</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>319</th>\n",
       "      <td>YO29232</td>\n",
       "      <td>A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZ...</td>\n",
       "      <td>China 2/3 Non Small Cell Lung Cancer Regional ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Active</td>\n",
       "      <td>0</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>431.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.76</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>354</th>\n",
       "      <td>ML28794</td>\n",
       "      <td>Single arm multi-center study investigating th...</td>\n",
       "      <td>UMBHER1 Umbrella_BELIS</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.04</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>654</th>\n",
       "      <td>ML28589</td>\n",
       "      <td>An open-label, multicenter Phase IIIb study in...</td>\n",
       "      <td>UmbHER1- Herceptin SC Preference/Safety in Her...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Active</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>866</th>\n",
       "      <td>ML28879</td>\n",
       "      <td>National Phase IIIB Prospective ,  Two-Cohort ...</td>\n",
       "      <td>UMBHER 1 Umbrella Safety of trastuzumab sc</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.04</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.04</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>997</th>\n",
       "      <td>YO29296</td>\n",
       "      <td>A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO...</td>\n",
       "      <td>Perjeta China regional 1L MBC HER2+ study</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Active</td>\n",
       "      <td>0</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>71.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1007</th>\n",
       "      <td>GO28053</td>\n",
       "      <td>An Open Label, Phase I Study to Evaluate the I...</td>\n",
       "      <td>Zelboraf Severe Hepatic Impairment Study (PMR #6)</td>\n",
       "      <td>Hepatic</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase I</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>9.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.69</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1028</th>\n",
       "      <td>GO28754</td>\n",
       "      <td>A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF M...</td>\n",
       "      <td>aPDL1 PHASE II in PD-L1-POSITIVE NSCLC pts</td>\n",
       "      <td>Birch</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Phase II</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>89.0</td>\n",
       "      <td>496.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.04</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.74</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1135</th>\n",
       "      <td>NO25390</td>\n",
       "      <td>An open-label, multicenter, single-arm, Phase ...</td>\n",
       "      <td>RO5185426 in pediatric pats in BRAFV600E melanoma</td>\n",
       "      <td>BRIM-P</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase I</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.57</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1140</th>\n",
       "      <td>ML29662</td>\n",
       "      <td>A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE I...</td>\n",
       "      <td>HER2+ ADVANCED BREAST CANCER</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Active</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 4</td>\n",
       "      <td>Phase IV</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>32.0</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.10</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.46</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1352</th>\n",
       "      <td>MO25515</td>\n",
       "      <td>An open-label, multicenter expanded access stu...</td>\n",
       "      <td>Study of RO5185426 in metastatic melanoma pati...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1489</th>\n",
       "      <td>GO29058</td>\n",
       "      <td>A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED,...</td>\n",
       "      <td>GDC-0032 HER2- HR+ phase III (LIP phase III)</td>\n",
       "      <td>SANDPIPER</td>\n",
       "      <td>Active</td>\n",
       "      <td>0</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>513.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.10</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.81</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1513</th>\n",
       "      <td>GO30182</td>\n",
       "      <td>A PHASE III, OPEN-LABEL, MULTICENTER, THREE-AR...</td>\n",
       "      <td>Phase 3 cobimetinib in combination with atezol...</td>\n",
       "      <td>COTEZO IMblaze370</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>328.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.01</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.90</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1525</th>\n",
       "      <td>ML40471</td>\n",
       "      <td>An Open-Label, Single arm, Multicenter Study t...</td>\n",
       "      <td>Atezolizumab's long-term safety in previously-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Active</td>\n",
       "      <td>0</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.01</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1665</th>\n",
       "      <td>ML29538</td>\n",
       "      <td>An Open-Label Study of Obinutuzumab (GA101) Pl...</td>\n",
       "      <td>Gazyva (GA101) Plus Benda CLL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Active</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Phase II</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>90.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.88</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1848</th>\n",
       "      <td>GO28625</td>\n",
       "      <td>A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF A...</td>\n",
       "      <td>Phase II Trial of Atezolizumab in NSCLC</td>\n",
       "      <td>FIR</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Phase II</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>15.0</td>\n",
       "      <td>109.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.07</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.79</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2004</th>\n",
       "      <td>CO39083</td>\n",
       "      <td>A PHASE Ib OPEN-LABEL STUDY EVALUATING THE SAF...</td>\n",
       "      <td>A PHASE Ib OPEN-LABEL STUDY EVALUATING THE SAF...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase Ib</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>22.0</td>\n",
       "      <td>25.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.43</td>\n",
       "      <td>0.49</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2107</th>\n",
       "      <td>BO22334</td>\n",
       "      <td>A phase III study of SC rituximab in combinati...</td>\n",
       "      <td>Ph III of MabThera SC w CHOP or CVP</td>\n",
       "      <td>SABRINA</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>44.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.04</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2126</th>\n",
       "      <td>GO01298</td>\n",
       "      <td>AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL OF ...</td>\n",
       "      <td>Ph 1b- 1st Line CLL GA101 chemo combo safety s...</td>\n",
       "      <td>GALTON</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase Ib</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2200</th>\n",
       "      <td>MO27782</td>\n",
       "      <td>A two-cohort, open-label, multicenter Phase II...</td>\n",
       "      <td>VELVET: Pertu+/-Trastu + Vino, 1st line Her2+ mBC</td>\n",
       "      <td>VELVET</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Phase II</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>36.0</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.01</td>\n",
       "      <td>0.01</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2225</th>\n",
       "      <td>ML29167</td>\n",
       "      <td>PHASE II TRIAL TO EVALUATE THE EFFICACY OF OBI...</td>\n",
       "      <td>Efficacy Obinutuzumab+ Benda in refract/relaps...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Clinical Closure</td>\n",
       "      <td>1</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Phase II</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>ONC</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.01</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.03</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>25 rows Ã— 56 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     STUDY_NUMBER                                   STUDY_FULL_TITLE  \\\n",
       "67        GO40241  A PHASE III, DOUBLE-BLINDED, MULTICENTER, RAND...   \n",
       "145       YO29233  A PHASE I, OPEN-LABEL STUDY TO ASSESS THE PHAR...   \n",
       "192       MO28113  A TWO-PART, RANDOMIZED PHASE III, DOUBLE-BLIND...   \n",
       "209       ML29282  A PHASE IV, MULTICENTER, OPEN-LABEL, SINGLE-AR...   \n",
       "215       YP25623  A multi-center, open label, single arm, multip...   \n",
       "319       YO29232  A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZ...   \n",
       "354       ML28794  Single arm multi-center study investigating th...   \n",
       "654       ML28589  An open-label, multicenter Phase IIIb study in...   \n",
       "866       ML28879  National Phase IIIB Prospective ,  Two-Cohort ...   \n",
       "997       YO29296  A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO...   \n",
       "1007      GO28053  An Open Label, Phase I Study to Evaluate the I...   \n",
       "1028      GO28754  A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF M...   \n",
       "1135      NO25390  An open-label, multicenter, single-arm, Phase ...   \n",
       "1140      ML29662  A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE I...   \n",
       "1352      MO25515  An open-label, multicenter expanded access stu...   \n",
       "1489      GO29058  A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED,...   \n",
       "1513      GO30182  A PHASE III, OPEN-LABEL, MULTICENTER, THREE-AR...   \n",
       "1525      ML40471  An Open-Label, Single arm, Multicenter Study t...   \n",
       "1665      ML29538  An Open-Label Study of Obinutuzumab (GA101) Pl...   \n",
       "1848      GO28625  A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF A...   \n",
       "2004      CO39083  A PHASE Ib OPEN-LABEL STUDY EVALUATING THE SAF...   \n",
       "2107      BO22334  A phase III study of SC rituximab in combinati...   \n",
       "2126      GO01298  AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL OF ...   \n",
       "2200      MO27782  A two-cohort, open-label, multicenter Phase II...   \n",
       "2225      ML29167  PHASE II TRIAL TO EVALUATE THE EFFICACY OF OBI...   \n",
       "\n",
       "                                      STUDY_SHORT_TITLE      STUDY_ACRONIM  \\\n",
       "67                                    Neoadjuvant NSCLC                NaN   \n",
       "145                                     China PK  Study                NaN   \n",
       "192       Pertuzumab + chemo+: platinum resistant women           PENELOPE   \n",
       "209     Open-label single arm study in first line advBC                NaN   \n",
       "215               PK study of GA101 in Chinese patients           GERSHWIN   \n",
       "319   China 2/3 Non Small Cell Lung Cancer Regional ...                NaN   \n",
       "354                              UMBHER1 Umbrella_BELIS                NaN   \n",
       "654   UmbHER1- Herceptin SC Preference/Safety in Her...                NaN   \n",
       "866          UMBHER 1 Umbrella Safety of trastuzumab sc                NaN   \n",
       "997           Perjeta China regional 1L MBC HER2+ study                NaN   \n",
       "1007  Zelboraf Severe Hepatic Impairment Study (PMR #6)            Hepatic   \n",
       "1028         aPDL1 PHASE II in PD-L1-POSITIVE NSCLC pts              Birch   \n",
       "1135  RO5185426 in pediatric pats in BRAFV600E melanoma             BRIM-P   \n",
       "1140                       HER2+ ADVANCED BREAST CANCER                NaN   \n",
       "1352  Study of RO5185426 in metastatic melanoma pati...                NaN   \n",
       "1489       GDC-0032 HER2- HR+ phase III (LIP phase III)          SANDPIPER   \n",
       "1513  Phase 3 cobimetinib in combination with atezol...  COTEZO IMblaze370   \n",
       "1525  Atezolizumab's long-term safety in previously-...                NaN   \n",
       "1665                      Gazyva (GA101) Plus Benda CLL                NaN   \n",
       "1848            Phase II Trial of Atezolizumab in NSCLC                FIR   \n",
       "2004  A PHASE Ib OPEN-LABEL STUDY EVALUATING THE SAF...                NaN   \n",
       "2107                Ph III of MabThera SC w CHOP or CVP            SABRINA   \n",
       "2126  Ph 1b- 1st Line CLL GA101 chemo combo safety s...             GALTON   \n",
       "2200  VELVET: Pertu+/-Trastu + Vino, 1st line Her2+ mBC             VELVET   \n",
       "2225  Efficacy Obinutuzumab+ Benda in refract/relaps...                NaN   \n",
       "\n",
       "          STUDY_STATUS  DB_LOCK_FLAG STUDY_PHASE_GROUP STUDY_PHASE  \\\n",
       "67              Active             0           Phase 3   Phase III   \n",
       "145             Active             0           Phase 1    Phase Ib   \n",
       "192   Clinical Closure             1           Phase 3   Phase III   \n",
       "209   Clinical Closure             1           Phase 4    Phase IV   \n",
       "215   Clinical Closure             1           Phase 1     Phase I   \n",
       "319             Active             0           Phase 3   Phase III   \n",
       "354   Clinical Closure             1           Phase 3   Phase III   \n",
       "654             Active             1           Phase 3   Phase III   \n",
       "866   Clinical Closure             1           Phase 3   Phase III   \n",
       "997             Active             0           Phase 3   Phase III   \n",
       "1007  Clinical Closure             1           Phase 1     Phase I   \n",
       "1028  Clinical Closure             1           Phase 2    Phase II   \n",
       "1135  Clinical Closure             1           Phase 1     Phase I   \n",
       "1140            Active             1           Phase 4    Phase IV   \n",
       "1352  Clinical Closure             1           Phase 3   Phase III   \n",
       "1489            Active             0           Phase 3   Phase III   \n",
       "1513  Clinical Closure             1           Phase 3   Phase III   \n",
       "1525            Active             0           Phase 3   Phase III   \n",
       "1665            Active             1           Phase 2    Phase II   \n",
       "1848  Clinical Closure             1           Phase 2    Phase II   \n",
       "2004  Clinical Closure             1           Phase 1    Phase Ib   \n",
       "2107  Clinical Closure             1           Phase 3   Phase III   \n",
       "2126  Clinical Closure             1           Phase 1    Phase Ib   \n",
       "2200  Clinical Closure             1           Phase 2    Phase II   \n",
       "2225  Clinical Closure             1           Phase 2    Phase II   \n",
       "\n",
       "          STUDY_TYPE THERAPEUTIC_AREA_REP  ... WITHDRAWN_SAFETY  \\\n",
       "67    Interventional                  ONC  ...              0.0   \n",
       "145   Interventional                  ONC  ...              0.0   \n",
       "192   Interventional                  ONC  ...              0.0   \n",
       "209   Interventional                  ONC  ...              0.0   \n",
       "215   Interventional                  ONC  ...              0.0   \n",
       "319   Interventional                  ONC  ...              0.0   \n",
       "354   Interventional                  ONC  ...              0.0   \n",
       "654   Interventional                  ONC  ...              0.0   \n",
       "866   Interventional                  ONC  ...              0.0   \n",
       "997   Interventional                  ONC  ...              0.0   \n",
       "1007  Interventional                  ONC  ...              0.0   \n",
       "1028  Interventional                  ONC  ...              0.0   \n",
       "1135  Interventional                  ONC  ...              0.0   \n",
       "1140  Interventional                  ONC  ...              0.0   \n",
       "1352  Interventional                  ONC  ...              0.0   \n",
       "1489  Interventional                  ONC  ...              0.0   \n",
       "1513  Interventional                  ONC  ...              0.0   \n",
       "1525  Interventional                  ONC  ...              0.0   \n",
       "1665  Interventional                  ONC  ...              0.0   \n",
       "1848  Interventional                  ONC  ...              0.0   \n",
       "2004  Interventional                  ONC  ...              0.0   \n",
       "2107  Interventional                  ONC  ...              0.0   \n",
       "2126  Interventional                  ONC  ...              0.0   \n",
       "2200  Interventional                  ONC  ...              0.0   \n",
       "2225  Interventional                  ONC  ...              0.0   \n",
       "\n",
       "     WITHDRAWN_OTHER_PRE_SPECIFIED WITHDRAWN_OTHER  \\\n",
       "67                             0.0            23.0   \n",
       "145                            0.0            85.0   \n",
       "192                            0.0            37.0   \n",
       "209                            0.0             1.0   \n",
       "215                            0.0            14.0   \n",
       "319                            0.0           431.0   \n",
       "354                            0.0             3.0   \n",
       "654                            0.0             8.0   \n",
       "866                            0.0            10.0   \n",
       "997                            0.0            71.0   \n",
       "1007                           0.0             9.0   \n",
       "1028                          89.0           496.0   \n",
       "1135                           0.0             4.0   \n",
       "1140                           0.0            32.0   \n",
       "1352                           0.0             2.0   \n",
       "1489                           0.0           513.0   \n",
       "1513                           0.0           328.0   \n",
       "1525                           0.0             0.0   \n",
       "1665                           0.0            90.0   \n",
       "1848                          15.0           109.0   \n",
       "2004                          22.0            25.0   \n",
       "2107                           0.0            44.0   \n",
       "2126                           0.0             2.0   \n",
       "2200                           0.0            36.0   \n",
       "2225                           0.0             2.0   \n",
       "\n",
       "     WITHDRAWN_ADVERSE_EVENTS_RATIO WITHDRAWN_SUBJECTIVE_RATIO  \\\n",
       "67                             0.00                       0.03   \n",
       "145                            0.00                       0.02   \n",
       "192                            0.00                       0.00   \n",
       "209                            0.02                       0.00   \n",
       "215                            0.02                       0.33   \n",
       "319                            0.00                       0.03   \n",
       "354                            0.09                       0.04   \n",
       "654                            0.02                       0.00   \n",
       "866                            0.05                       0.02   \n",
       "997                            0.00                       0.03   \n",
       "1007                           0.00                       0.00   \n",
       "1028                           0.00                       0.08   \n",
       "1135                           0.00                       0.00   \n",
       "1140                           0.03                       0.22   \n",
       "1352                           0.00                       0.00   \n",
       "1489                           0.00                       0.10   \n",
       "1513                           0.00                       0.08   \n",
       "1525                           0.00                       0.00   \n",
       "1665                           0.00                       0.00   \n",
       "1848                           0.00                       0.07   \n",
       "2004                           0.00                       0.08   \n",
       "2107                           0.00                       0.06   \n",
       "2126                           0.00                       0.02   \n",
       "2200                           0.02                       0.00   \n",
       "2225                           0.00                       0.00   \n",
       "\n",
       "     WITHDRAWN_NON_COMPLIANCE_RATIO WITHDRAWN_PROTOCOL_DEVIATIONS_RATIO  \\\n",
       "67                             0.00                                0.01   \n",
       "145                            0.00                                0.00   \n",
       "192                            0.00                                0.00   \n",
       "209                            0.12                                0.00   \n",
       "215                            0.00                                0.02   \n",
       "319                            0.00                                0.05   \n",
       "354                            0.11                                0.00   \n",
       "654                            0.03                                0.03   \n",
       "866                            0.04                                0.00   \n",
       "997                            0.00                                0.06   \n",
       "1007                           0.00                                0.08   \n",
       "1028                           0.00                                0.04   \n",
       "1135                           0.00                                0.00   \n",
       "1140                           0.00                                0.10   \n",
       "1352                           0.00                                0.00   \n",
       "1489                           0.00                                0.03   \n",
       "1513                           0.00                                0.01   \n",
       "1525                           0.01                                0.00   \n",
       "1665                           0.00                                0.00   \n",
       "1848                           0.00                                0.03   \n",
       "2004                           0.00                                0.00   \n",
       "2107                           0.00                                0.04   \n",
       "2126                           0.02                                0.05   \n",
       "2200                           0.01                                0.01   \n",
       "2225                           0.01                                0.00   \n",
       "\n",
       "     WITHDRAWN_SAFETY_RATIO WITHDRAWN_OTHER_PRE_SPECIFIED_RATIO  \\\n",
       "67                      0.0                                0.00   \n",
       "145                     0.0                                0.00   \n",
       "192                     0.0                                0.00   \n",
       "209                     0.0                                0.00   \n",
       "215                     0.0                                0.00   \n",
       "319                     0.0                                0.00   \n",
       "354                     0.0                                0.00   \n",
       "654                     0.0                                0.00   \n",
       "866                     0.0                                0.00   \n",
       "997                     0.0                                0.00   \n",
       "1007                    0.0                                0.00   \n",
       "1028                    0.0                                0.13   \n",
       "1135                    0.0                                0.00   \n",
       "1140                    0.0                                0.00   \n",
       "1352                    0.0                                0.00   \n",
       "1489                    0.0                                0.00   \n",
       "1513                    0.0                                0.00   \n",
       "1525                    0.0                                0.00   \n",
       "1665                    0.0                                0.00   \n",
       "1848                    0.0                                0.11   \n",
       "2004                    0.0                                0.43   \n",
       "2107                    0.0                                0.00   \n",
       "2126                    0.0                                0.00   \n",
       "2200                    0.0                                0.00   \n",
       "2225                    0.0                                0.00   \n",
       "\n",
       "     WITHDRAWN_OTHER_RATIO  \n",
       "67                    0.06  \n",
       "145                   0.71  \n",
       "192                   0.18  \n",
       "209                   0.02  \n",
       "215                   0.29  \n",
       "319                   0.76  \n",
       "354                   0.03  \n",
       "654                   0.07  \n",
       "866                   0.04  \n",
       "997                   0.29  \n",
       "1007                  0.69  \n",
       "1028                  0.74  \n",
       "1135                  0.57  \n",
       "1140                  0.46  \n",
       "1352                  0.00  \n",
       "1489                  0.81  \n",
       "1513                  0.90  \n",
       "1525                  0.00  \n",
       "1665                  0.88  \n",
       "1848                  0.79  \n",
       "2004                  0.49  \n",
       "2107                  0.11  \n",
       "2126                  0.05  \n",
       "2200                  0.17  \n",
       "2225                  0.03  \n",
       "\n",
       "[25 rows x 56 columns]"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "subset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
